4Hagan H, Thiede H, Des J. Hepatitis C virus infection among injection drag users: survival analysis of time to seroconversion[J]. Epidemiology, 2004,15 : 543 - 549.
二级参考文献42
1戴志澄 祁国明.中国病毒性肝炎血清流行病学调查[M].科学技术文献出版社,1997.39-58.
2Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol, 2003, 36:47-53.
3WHO Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, antwerp, belgium. J Viral Hepat,1999, 6:35-47.
4Armstrong GL, Alter MJ, MeQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of ehronle liver disease in the United States. Hepatology,2000, 31:777-782.
5Alter MJ, Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C virus infection in the United States, 1988-1994. N Engl J Med, 1999, 341:556-562.
6Lowe D, Cotton R. Hepatitis C: a review of Australia's response. Publications Production Unit, Commonwealth department of health and aged care, Commonwealth of Australia, Canberra, 1999.
7Villano SA, Vlahov D, Nelson KE, et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore,Maryland. J Clin Microbiol, 1997, 35: 3274-3277.
8Hollinger FB, Kirtava A, Oakley M, et al. Blood safety monitoring among patients with bleeding disorders-United States, May1998-June, 2002. MMWR, 2003,1152-1154.
9Takano S, Nakamura K, Kawai S, et al. Prospective assessment of donor blood screening for antibody to hepatitis C virus by first-and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology, 1996,23:708-712.
10Gonzalez A, Esteban JI, Madoz P, et al. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis:final report of a prospective trial. Hepatology, 1995,22:439-445.
